Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to severe hemophilia A. The AFFINE study achieved its primary objective of non-inferiority, as well as superiority, of total annualized bleeding rate (ABR) from Week 12 through at least 15 months of follow up post-infusion compared with routine Factor VIII (FVIII) replacement prophylaxis treatment.

Data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) study, the first and largest clinical trial of pre-symptomatic Alzheimer's disease, is now widely available to researchers studying the condition. The comprehensive dataset has already yielded key insights about Alzheimer’s disease, which affects nearly seven million people in the United States, and sharing the data opens avenues for further progress.

Antibiotics are crucial in modern medicine, but their widespread use has led to antibiotic-resistant bacteria, posing a serious public health threat. A new study highlights the potential of random antimicrobial peptide mixtures to significantly reduce the risk of resistance evolution compared to single peptides. These findings support the development of new antimicrobial strategies, emphasizing the need for innovative solutions to outpace bacterial resistance and safeguard public health.

Relapsed/refractory acute myeloid leukemia (AML), a so-called blood cancer, has an extremely poor prognosis because of resistance to anti-cancer drugs and frailty of the patient’s organ functions. A type of anti-tumor immunotherapy called allogeneic hematopoietic cell transplantation, which can exert anti-cancer effect accompanied by severe toxicity, is often performed for patients who are hard to treat with chemotherapy, but relapse still remains.

Peek inside the human genome and, among the 20,000 or so genes that serve as building blocks of life, you’ll also find flecks of DNA left behind by viruses that infected primate ancestors tens of millions of years ago. These ancient hitchhikers, known as endogenous retroviruses, were long considered inert or 'junk' DNA, defanged of any ability to do damage. New CU Boulder research published July 17 in the journal Science Advances shows that, when reawakened, they can play a critical role in helping cancer survive and thrive.